Lansing based Bioport is given the go ahead to test an approved anthrax vaccine on humans. The Food and Drug Administration okayed the study which will test Bioport's improved Biothrax vaccine. It contains an immune stimulating molecule that could reduce the number of doses needed to protect against an anthrax infection. Currently, six doses are given over an eighteen month period but Bioport hopes to bring the dosage down to three.
Bioport spokesperson Kim Brennan Root says the company has been working on the improved vaccine for about a year and within weeks will begin testing it on humans. Data collected from the study will be used to determine whether or not Bioport will take its improved vaccine to the next level. Testing could take weeks, maybe even months.
News Ten contacted the FDA and its spokesperson declined to comment.